Dihydrokaempferol

Dihydrokaempferol

SCHEMBL29367287

O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)cc2)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.80
MEN1 O00255 4/20 0.80
KMT2A Q03164 4/20 0.80
MAPT P10636 4/20 0.80
HSD17B10 Q99714 4/20 0.80
ALOX15 P16050 4/20 0.80
ALOX12 P18054 3/20 0.80
RECQL P46063 2/20 0.80
SOST Q9BQB4 2/20 0.80
POLB P06746 2/20 0.80
CYP1A2 P05177 2/20 0.80
KDM4E B2RXH2 2/20 0.80
GAA P10253 2/20 0.80
HIF1A Q16665 2/20 0.80
NFKB1 P19838 1/20 0.80
MAPK1 P28482 1/20 0.80
SYNJ2 O15056 1/20 0.74
APP P05067 1/20 0.74
XDH P47989 1/20 0.66
CBS P35520 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dihydrokaempferol SCHEMBL31026899 1.00 CYP3A4 (0.80) CYP3A4MEN1KMT2AMAPTHSD17B10
Dihydrokaempferol SCHEMBL2036629 1.00 CYP3A4 (0.80) CYP3A4MEN1KMT2AMAPTHSD17B10
Dihydrokaempferol SCHEMBL3437565 1.00 CYP3A4 (0.80) CYP3A4MEN1KMT2AMAPTHSD17B10
Dihydrokaempferol SCHEMBL29454736 1.00 CYP3A4 (0.80) CYP3A4MEN1KMT2AMAPTHSD17B10
Dihydrokaempferol SCHEMBL13354175 1.00 CYP3A4 (0.80) CYP3A4MEN1KMT2AMAPTHSD17B10
Dihydrokaempferol SCHEMBL39319 1.00 CYP3A4 (0.80) CYP3A4MEN1KMT2AMAPTHSD17B10
Dihydrokaempferol SCHEMBL3438673 1.00 CYP3A4 (0.80) CYP3A4MEN1KMT2AMAPTHSD17B10
Dihydrokaempferol SCHEMBL31547241 0.93 MAPT (0.70) CYP3A4MEN1KMT2AMAPTHSD17B10
Pinobaksin SCHEMBL14461145 0.91 MAPT (0.75) CYP3A4MEN1KMT2AMAPTHSD17B10
Pinobaksin SCHEMBL1045054 0.91 MAPT (0.75) CYP3A4MEN1KMT2AMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454714-B2 Monbretin A (MbA) synthesis using a heterologous nucleic acid(s) encoding A MbA pathway enzyme THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2025-10-28 US claimed
EP-4573202-A2 FLAVONOID BIOPRODUCTION USING MICROORGANISM HOSTS Debut Biotechnology, Inc. (US) 2025-06-25 EP claimed
CN-120019153-A Biological production of flavonoids using microbial hosts 德比生物技术公司 2025-05-16 CN claimed
WO-2024040211-A2 FLAVONOID BIOPRODUCTION USING MICROORGANISM HOSTS Debut Biotechnology, Inc. (US) 2024-02-22 WO claimed
EP-4323528-A1 FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS Debut Biotechnology, Inc. (US) 2024-02-21 EP claimed
CN-117413066-A Biological production of flavonoids and anthocyanins using a microbial host 德比生物技术公司 2024-01-16 CN claimed
US-20230000797-A1 COMPOSITIONS AND METHODS FOR TREATING MOTOR DISORDERS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2023-01-05 US claimed
WO-2022221392-A1 FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS Debut Biotechnology, Inc. (US) 2022-10-20 WO claimed
US-20220333087-A1 FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS Debut Biotechnology, Inc. 2022-10-20 US claimed
US-11426366-B2 Compositions and methods for treating motor disorders ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSSITY OF ARIZONA (US) 2022-08-30 US claimed
CN-122038322-A 4-Hydroxyphenylacetic acid 3-monooxygenase mutant and application thereof 南京林业大学 2026-05-15 CN disclosed
EP-4702038-A1 METHOD OF PRODUCING POLYPHENOLS Nicoventures Trading Limited (GB) 2026-03-04 EP disclosed
US-20250331479-A1 Anthocyanin-Free Broccoli BEJO ZADEN BV (NL) 2025-10-30 US disclosed
US-12454714-B2 Monbretin A (MbA) synthesis using a heterologous nucleic acid(s) encoding A MbA pathway enzyme THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2025-10-28 US disclosed
EP-4627099-A2 PROCESS FOR MAKING FLAVANONE DERIVATIVES Firmenich SA (CH) 2025-10-08 EP disclosed
CN-114657205-A Application of OsF 3' H gene in resisting pathogens 中国科学院分子植物科学卓越创新中心 2022-06-24 CN disclosed
CN-114480532-A Application of strain CH18 in preparation of anthocyanin and other flavonoid compounds 北京理工大学 2022-05-13 CN disclosed
CN-114364265-A Flavanone derivatives and their use as sweetness enhancers 弗门尼舍有限公司 2022-04-15 CN disclosed
CN-114107329-A Method for knocking out dihydroflavonol-4-reductase gene of tobacco to improve rutin content by using gene editing technology and application 云南中烟工业有限责任公司 2022-03-01 CN disclosed
CN-111254150-B Ginkgo GbFLSa gene and expression protein and application thereof 南京林业大学 2022-02-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000797-A1 COMPOSITIONS AND METHODS FOR TREATING MOTOR DISORDERS SNCA, PARK7, COMT CYP3A4 3627/4885MEN1 4514/4885KMT2A 55/4885
US-11426366-B2 Compositions and methods for treating motor disorders COMT, SNCA, PARK7 CYP3A4 3312/4885MEN1 4560/4885KMT2A 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.